INDEX TO VOLUMES 1-3
JUNE 1977 to DECEMBER 1979

AUTHORS

Abdel-Aziz, S.A.M.; Kassem, A.A.; Abou-Taleb, A.E.; and Abdel-Hady, S.S. The effect of a coloring agent on properties of mixed films of acrylic. Dec. 1979, p. 38.
See also Kassem, A.A.

Abdel-Hady, S.S. See Abdel-Aziz, S.A.M., and Kassem, A.A.

Abou-Taleb, A.E. See Abdel-Aziz, S.A.M., and Kassem, A.A.

Akers, Michael J.; Attia, Ismail A.; and Avis, Kenneth E. Understanding and utilizing F_0 values. May 1978, p. 30.

Alegnani, William C. The impact of GMPs on the significance of sterility testing. Dec. 1979, p. 44.

Attia, Ismail A. See Akers, Michael J.

Avis, Kenneth E. See Akers, Michael J.

Baker, Selwyn J. See Hallberg, Leif.

Ball, LuAnn. See Smolen, Victor F.

Banes, Daniel. Dissolution standards in USP. Aug. 1978, p. 46.
An inquiry into the LAL and rabbit pyrogen tests. July 1979, p. 28.

Barr, William R., and Cotterill, Harry H. Lot-size determination for multipackage products. March 1978. p. 46.

Bassen, Jonas L. FDA's CGMP regulations and quality audits. July 1977, p. 31.

Bathe, Peter. London Letter. Monthly column. Sept. 1979–Dec. 1979.

Bell, Christopher. Pressure-sensitive labels: standards in quality control. June 1978, p. 56.

Benmaman. Joseph D. See Warren, James W. Jr.

Bickmore, William D. Jr.; Champa, Rudolph A.; and Olson, Wayne P. Recycling-tangential flow in microporous cartridge filtration. Nov. 1977, p. 55.

Bier, Hans-Peter. See Leuenberger, Hans.

Borowsky, Allen. Identification of clinically significant anaerobic bacteria. Jan. 1979, p. 32.

Brady, Edward S. As I see it. Feb. 1979, p. 41.
Toward détente. July 1977, p. 11.

Brusick, David J. Automated plate-counting assays in the Ames *Salmonella*/microsome mutagenicity test. Jan. 1978, p. 37.

Burditt, George M. Parenteral drugs: a lawyer's viewpoint. May 1978, p. 12.

Butler, Robert N. Drugs and aging: research, education, and cooperation. Oct. 1978, p. 8.

Caldwell, Larry; Cargill, Robyn; Ebert, William R.; and Windheuser, John J. The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. July 1979, p. 52.

Cargill, Robyn. See Caldwell, Larry.

Challman, Rick. A natural gas metering system. Dec. 1978, p. 36.

Champa, Rudolph A. See Bickmore, William D. Jr.

Chichester, C.O. See Hallberg, Leif.

Clements, Barbara, and Swenson, Ronald. Automated microscopy for contamination control. Jan. 1978, p. 42.

Clougherty, Leo E. UV/Vis spectrophotometers: quality control and troubleshooting. April 1978, p. 68.

Cocks, Douglas L. Drug-firm productivity, R&D, and public policy. Sept. 1977, p. 20.

Cole, Jack C. Considerations in application of bacteria-retentive air vent-filters. June 1977, p. 49.

Cole, Jack C., and Shumsky, Robert H. Filter sizing for economics: liquid systems. Nov. 1977, p. 38.

Cook, James D. See Hallberg, Leif.

Cooper, Jack. Excipients and dosage-form development. April 1979, p. 12.

Cotterill, Harry H. See Barr, William R.

Cox, Don C.; Douglas, Carol C.; Furman, William B.; Kirchhoefer, Ross D.; Myrick, James W.; and Wells, Clyde E. Guidelines for dissolution testing. April 1978, p. 40.

Creevy, Robert J. Drug quality: who has the answer? Feb. 1979, p. 10.

Crout, J. Richard. Drug-product substitution and therapeutic equivalence. June 1979, p. 56.

Crumpley, James A. Interviews that win jobs. Oct. 1979, p. 42.
Job hunting: a professional approach. June 1979, p. 45.

Davis, Joel S. Requirements for expiration dating and stability testing in the United States. Oct. 1979, p. 64.

De Geeter, Melvin J. See Pope, David G.

Dell, Leonard A. Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Aug. 1979, p. 46.

DeLuca, Patrick P. A commitment to excellence and awareness. July 1979, p. 10.
First International Conference on Pharmaceutical Technology. Aug. 1977, p. 34.

DeMaeyer, E.M. See Hallberg, Leif.

De Vecchi, Franco A. Training personnel to work in sterile environments. Aug. 1978, p. 40.

DeVisser, Arnold D. See Enzinger, Michael.

Dickinson, James. Drug-quality regulation and the pursuit of excellence. Aug. 1978, p. 21.
FDA's Kennedy has a prescription for drug science: upgrade toxicology. June 1978, p. 60.
FDA yields to industry positions on Good Manufacturing Practices. Dec. 1978, p. 25.
Industry-agency relations: an interview with J. Richard Crout. March 1978, p. 39.
An interview with Donald Kennedy. Dec. 1977, p. 33.
Jere Goyan: New face at FDA. Nov. 1979, p. 21.
Public monographs: the centerpiece of the new drug bill. May 1978, p. 37.
Self-policing and free enterprise: an interview with Representative Paul Rogers. April 1978, p. 61.
Therapeutic equivalence in a restructured drug market. April 1979, p. 72.
The threshold of a new drug-production era. Feb. 1978, p. 41.
Washington report. Monthly column. June 1977–Dec. 1979.

Dixon, John R. Quality assurance and quality control of commercially prepared microbiological powder media. Aug. 1977, p. 27.

Doluisio, James T. Bioavailability and bioequivalence regulations: an overview. July 1978, p. 32.

Douglas, Carol C. See Cox, Don C.

Dreher, Dieter. See Lehmann, Klaus.

Drobeck, Hans P. The impact of GLP regulations on an industrial toxicology laboratory. Aug. 1979, p. 34.
Duarte, James E., and Vest, Deborah K. Validating alternate laboratory assay methods. May 1979, p. 60.
Eaton, Frank D. The real GMPs. Nov. 1978, p. 58.
Ebert, William R. Bioavailability of theophylline in soft-gelatin capsules. Oct. 1979, p. 60.
Soft elastic gelatin capsules: a unique dosage form. Oct. 1977, p. 44.
See also Caldwell, Larry.
Enzinger, Michael; DeVisser, Arnold D.; and Townsend, Michael W. Steam-sterilization validation studies for manufacturing equipment. Aug. 1977, p. 31.
Fogarty, Michael G. Radiosterilization in industry today. June 1978, p. 34.
Franklin, Gary. See Murty, Ram.
Furman, William B. See Cox, Don C.
Gakenheimer, Walter C. The effects of the new GLP regulations on nonclinical biomedical research. Dec. 1979, p. 34.
Giorgio, Robert J. Considerations in the design of hot circulating water-for-injection systems. Dec. 1978, p. 18.
Gordon, James. See Dickinson, James, Washington report.
Green, Barbara L., and Litsky, Warren. Evaluation of a closed system for sterility testing of parenterals. Nov. 1979, p. 72.
Haddad, William F. The battle is over, but . . . . May 1979, p. 10.
Hallberg, Leif; Baker, Selwyn J.; Chichester, C.O.; Cook, James D.; DeMaeyer, E.M.; Newmark, Harold; Shapiro, H. Louis; and Teply, Lester J. Iron deficiency: a challenge to the pharmaceutical industry. Oct. 1979, p. 34.
Halleck, Frank E. Thermal solution sterilization. June 1978, p. 48.
Hanson, Royal A. See Hanson, William A.
Hanson, William A. Can dissolution testing be a precise method? Aug. 1979, p. 8.
Solving the puzzle of random variables in dissolution testing. Oct. 1977, p. 30.
Hanson, William A., and Hanson, Royal A. Effects of moisture on the dissolution rate of prednisone tablets. March 1979, p. 42.
Harper, George F. See Kemper, Clarence A.
Hauser, Bud. How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Oct. 1979, p. 52.
Heller, William M. On creating a compendial organization. Nov. 1979, p. 12.
Hess, Hans. Tablets under the microscope. Sept. 1978, p. 36.
Hile, Joseph P. A government success story. June 1977, p. 45.
Hopkins, George H. Improved procedures for selection of rubber closures. June 1978, p. 8.
The pharmaceutical industry today. June 1977, p. 16.
Horan, John J. Prospects for the 1980s. Sept. 1979, p. 24.
Huberfield, David B. Tablet coating: ladles to computers. Oct. 1977, p. 52.
Jensen, Mona D. The automation of cell-culture techniques. Feb. 1978, p. 22.
Johnston, Peter R., and Meltzer, Theodore H. Comments on organism-challenge levels in sterilizing-filter efficiency testing. Nov. 1979, p. 66.
Kamowski, Michael. See Sirota, Marvin.
Kapoor, John. See Murty, Ram.
Kapoor, John, and Murty, Ram. Pretreatment of rubber closures for parenteral containers. Nov. 1977, p. 53.
Kasdan, Harvey L. Production-line visual recognition systems. Aug. 1977, p. 18.
Kassem, A.A. See Abdel-Aziz, S.A.M.
Kassem, A.A.; Abdel-Aziz, S.A.M.; Abou-Taleb, A.E.; and Abdel-Hady, S.S. Some factors that affect the properties of mixed films of acrylic. Sept. 1979, p. 70.
Kemper, Clarence A., and Harper, George F. Probe-induced errors in temperature measurement. Nov. 1978, p. 48.
Kennedy, Donald. The imperatives of drug-law revision. Jan. 1978, p. 10.
A year for drug-law reform. Jan. 1979, p. 16.
Kennedy, Edward M. Some observations concerning drug testing. March 1978, p. 10.
Kippenhan, Nancy. Hazardous-chemical safety training. Feb. 1979, p. 64.
Kirchhoefer, Ross D. See Cox, Don C.
Kladko, Martin. Extra quality: is it a waste? May 1979, p. 22.
Knapp, Gene. Bioavailability and bioequivalence regulations: an FDA perspective. July 1978, p. 22.
Dissolution testing: its increasing role. Sept. 1977, p. 12.
Krummen, Kurt; Maxl, Friedrich; and Nachtmann, Friedrich. The use of HPLC in the quality control of oxytocin. Sept. 1979, p. 76.
Lasagna, Louis. Prescription for an FDA commissioner. Oct. 1979, p. 14.
Laubach, Gerald D. Innovation and the drug reform act of 1978. Aug. 1978, p. 14.
Leahy, Timothy J., and Sullivan, Mary J. Validation of bacterial-retention capabilities of membrane filters. Nov. 1978, p. 64.
Lehmann, Klaus, and Dreher, Dieter. Coating small particles with acrylic resins. March 1979, p. 52.
Lepore, Paul D. FDA's Good Laboratory Practice regulations. June 1979, p. 70.
Leuenberger, Hans; Bier, Hans-Peter; and Sucker, Heinz B. Theory of the granulating-liquid requirement in the conventional granulation process. June 1979, p. 60.
Lieberman, Alvin. Free air monitoring of nonviable aerosol particles: part I. Feb. 1979, p. 70.
Free air monitoring of nonviable aerosol particles: part II. March 1979, p. 60.
Verifying the efficiency of air-cleanliness control systems. Sept. 1977, p. 32.
Litsky, Warren. See Green, Barbara L.
Lloyd, Thomas R. An automated dispensing and data-collection system. Dec. 1977, p. 20.
Loftus, Bernard T. Human injectable drugs: an FDA perspective. Nov. 1977, p. 44.
Luce, Gerald T. Cellulose acetate phthalate: a versatile enteric coating. June 1977, p. 27.
Disintegration of tablets enteric coated with cellulose acetate phthalate. Oct. 1978, p. 51.
Lukaszewicz, Raymond C. Microporous-filter sanitization of large-volume product and feed-water systems. Aug. 1979, p. 40.
Lukaszewicz, Raymond C.; Tanny, Gerald B.; and Meltzer, Theodore H. Membrane-filter characterizations and their implications for particulate retention. Nov. 1978, p. 76.
Lykens, Donald N. Edible printing inks. Feb. 1979, p. 56.
McAllister, Warren A.; Sancilio, Frederick D.; and Martin, G. William. The use of Fourier-transform infrared spectroscopy in quality assurance. April 1979, p. 50.
McCrone, Walter C. Identification of parenteral particulate contaminants. May 1978, p. 56.
McDonald, John C. Automated HPLC systems: a total approach. April 1978, p. 78.
McGinity, James W. Solving dissolution problems with solid dispersions. March 1978, p. 50.
McKendrick, Martin D. See Mazur, Paul E.
Madan, Parshotam L. Methods of preparing microcapsules; coacervation, or phase separation. Feb. 1978, p. 30.
Methods of preparing microcapsules: interfacial polymerization. Sept. 1978, p. 68.
Methods of preparing microcapsules: mechanical methods. Aug. 1978, p. 24.
Microencapsulation: an overview. Dec. 1977, p. 28.
Manning, Joachim E. Biocontainment process station for parenteral manufacturing. Nov. 1979, p. 78.
Manning, Joachim E., and Moore, Jim. Aseptic control: where to start. June 1977, p. 54.
Martin, G. William. See McAllister, Warren A.
Maxl, Friedrich. See Krummen, Kurt.
Mazur, Paul E., and McKendrick, Martin D. Automated pyrogen-testing system. May 1979, p. 42.
Meltzer, Theodore H. The extension of drug industry practice to cosmetics manufacture. Dec. 1977, p. 14.
See also Johnston, Peter R.; Lukaszewicz, Raymond C.
Mendes, Robert W., and Roy, Suva B. Tableting excipients: part I.

March 1978, p. 32.
Tableting excipients: part II. Sept. 1978, p. 60.
Tableting excipients: part III. March 1979, p. 68.
Miller, James A. Apparatus and instrumentation for tablet dissolution testing. July 1977, p. 18.
Mohar, J. William. See Obremski, Robert J.
Moore, Jim. See Manning, Joachim E.
Moreno, Carlos W., and Reeves, Allan T. Acceptance sampling for small fraction defectives. July 1979, p. 40.
Morgan, Stanley L., and Spotts, Marlin R. How to select a pharmaceutical freeze-drying system. Nov. 1979, p. 94.
Munsey, Rodney R. Legal implications for the absolute sterility concept. Nov. 1979, p. 56.
Murty, Ram. See Kapoor, John.
Murty, Ram, and Kapoor, John. Applications of the osmometer in the manufacture of certain parenteral preparations. July 1977, p. 37.
Murty, Ram; Kapoor, John; and Franklin, Gary. In-process controls during the manufacture of injectables. Nov. 1977, p. 52.
Myrick, James W. See Cox, Don C.
Nachtmann, Friedrich. See Krummen, Kurt.
Nash, Robert A. Process validation for solid dosage forms. June 1979, p. 104.
Needham, Thomas E. Jr. See Warren, James W. Jr.
Nelson, Lita L. Removal of pyrogens from parenteral solutions by ultrafiltration. May 1978, p. 46.
Nelsen, Lita L., and Reti, Adrian R. Ultrafiltration in plasma fractionation. May 1979, p. 50.
Newmark, Harold. See Hallberg, Leif.
Obremski, Robert J., and Mohar, J. William. Computerized infrared techniques for pharmaceutical-formulation quality control. April 1979, p. 58.
Oddis, Joseph A. The pharmacist's role in health-care cost containment. Nov. 1978, p. 8.
Ogden, John E. A Weibull shelf-life model for pharmaceuticals. Oct. 1978, p. 44.
Olson, W.P. Validation and qualification of filtration systems for bacterial removal. Nov. 1979, p. 84.
See also Bickmore, William D. Jr.
Osberger, Thomas F. Tableting characteristics of pure crystalline fructose. June 1979, p. 80.
Parascandola, John. The development of the modern pharmaceutical industry. Oct. 1979, p. 46.
Parish, Preston S. Drug regulations in the public interest. Sept. 1978, p. 8.
Poole, John W. Bioavailability and bioequivalence regulations: how will they impact on product development? July 1978, p. 28.
Pope, David G.; Tsuji, Kiyoshi; Robertson, John H.; and DeGeeter, Melvin J. Raw material microbial-count reduction via cobalt 60 irradiation. Oct. 1978, p. 30.
Porter, Stuart C. Aqueous film coating: an overview. Sept. 1979, p. 54.
Pyatt, Charles F. See Terselic, Richard A.
Reeves, Allan T. See Moreno, Carlos W.
Reti, Adrian R. See Nelsen, Lita L.
Rico, Diana. Public image, patent status and "paper" NDAs: an FDA roundtable. July 1979, p. 32.
Riggs, Thomas H. Audits. Oct. 1977, p. 24.
Communication of attitude as a regulatory factor. Oct. 1978, p. 27.
Devices decrease drug domination. June 1977, p. 31.
IRLG. Aug. 1978, p. 52.
No new nonofficial drugs. June 1977, p. 18.
The point of the Pinto. May 1978, p. 14.
Stability. Jan. 1978, p. 21.
$10,000 per day? Feb. 1978, p. 66.
Robertson, John H. See Pope, David G.
Robertson, John L. Drug-safety evaluation using computerized data processing. May 1978, p. 50.
Rowell, Ted Jr. The drug reform act: a reprieve. March 1979, p. 8.
Roy, Suva B. See Mendes, Robert W.
Rumsfield, Donald. Is the regulatory process working? Dec. 1979, p. 12.
Sampson, Allan R. Multivariate statistical analysis in pharmaceutical research. Jan. 1979, p. 36.
Sancilio, Frederick D. See McAllister, Warren A.
Scheffler, Michael. See Smolen, Victor F.
Schneller, George H. Antibiotic batch certification: a regulatory device that has outlived its usefulness. Nov. 1979, p. 47.
Shapiro, H. Louis. See Hallberg, Leif.
Shevlin, Edward J. The Day-Nauta mixer-processor. March 1978, p. 56.
Shroff, Arvin P. Drug-quality surveillance of Rx and OTC drug products. Dec. 1979, p. 28.
Shumsky, Robert H. See Cole, Jack C.
Simmons, Paul L. Sterilizer validation. April 1979, p. 68.
Sirota, Marvin; Kamowski, Michael; and Wozniak, Mark. Use of regression analysis in packaging inspection. June 1978, p. 40.
Skelly, Jerome P. Dissolution testing — need for standardization. Oct. 1977, p. 12.
Implementation of the bioavailability/bioequivalence regulations. Jan. 1978, p. 28.
Smolen, Victor F. Instrumentation in futuristic pharmaceutics. April 1978, p. 10.
In vitro drug-product bioequivalency requirements: what can they become? Sept. 1977, p. 26.
Smolen, Victor F.; Ball, LuAnn; and Scheffler, Michael. Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. June 1979, p. 88.
Spotts, Marlin R. See Morgan, Stanley L.
Stanford, Edward A., and Wardle, Thomas J. Special design considerations for large-production freeze dryers. Nov. 1977, p. 59.
Steinbach, Marianne. See Woodward, Carl R. Jr.
Stetler, C. Joseph. The challenge of self-regulation. June 1979, p. 8.
A drug by any other name . . . ? July 1978, p. 8.
Economic incentive: the key to cost-effective medicine. July 1979, p. 20.
Patient package inserts. Aug. 1977, p. 10.
Stewart, David. The use of x-ray fluorescence in control of pharmaceutical products. April 1978, p. 54.
Sucker, Heinz B. See Leuenberger, Hans.
Sullivan, Mary J. See Leahy, Timothy J.
Swenson, Ronald. See Clements, Barbara.
Tanny, Gerald B. See Lukaszewicz, Raymond C.
Teply, Lester J. See Hallberg, Leif.
Terselic, Richard A., and Pyatt, Charles F. Strategies for surveillance of drug quality by FDA. Jan. 1979, p. 26.
Townsend, Michael W. See Enzinger, Michael.
Tsuji, Kiyoshi. See Pope, David G.
Tuthill, Samuel M. Bulk pharmaceutical chemicals: good manufacturing practice. Feb. 1979, p. 48.
Tyler, Varro E. Financial support for graduate education. Feb. 1978, p. 8.
Valentino, Joseph G. USP and antibiotic standardization. Sept. 1979, p. 60.
Vest, Deborah K. See Duarte, James E.
Wardle, Thomas J. See Stanford, Edward A.
Warren, James W. Jr.; Needham, Thomas E. Jr.; and Benmaman, Joseph D. Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. Dec. 1978, p. 30.
Wells, Clyde E. See Cox, Don C.
Willing, Wilfried G. Short-term hot-air sterilization by the laminar-flow process. May 1979, p. 68.
Windheuser, John J. See Caldwell, Larry.
Witt, Hugh E. A government-wide approach to quality assurance. June 1977, p. 44.
Woodward, Carl R. Jr., Reflections on the status of immunization and therapy. Nov. 1977, p. 12.
Woodward, Carl R. Jr., and Steinbach, Marianne. Further observations on a practical method for the microbiological examination of OTC products. June 1977, p. 39.
Wozniak, Mark. See Sirota, Marvin.

SUBJECTS

ACRYLICS

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.

The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.

Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.

ADVERTISING

"Don't compare drug with drug," in Washington report. James Dickinson. June 1978, p. 20.

"FTC overtures to FDA," in Washington report. James Dickinson. April 1978, p. 123.

"The no-holds-barred war," in Washington report. James Dickinson. March 1978, p. 20.

"When ads mustn't tell the truth," in Washington report. James Dickinson. Feb. 1979, p. 21.

AEROSOLS

The extension of drug industry practice to cosmetics manufacture. Theodore H. Meltzer. Dec. 1977, p. 14.

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

AGING

Drugs and aging: research, education, and cooperation. Robert N. Butler. Oct. 1978, p. 8.

ANAEROBES (see also MICROBIOLOGY)

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

ANTIBIOTICS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.

"A change in antibiotic regulations," in Washington report. James Dickinson. Oct. 1977, p. 73.

"Extensive changes in the antibiotic regulations," in Washington report. James Dickinson. May 1978, p. 62.

"The last OTC antibiotics," in Washington report. James Dickinson. March 1978, p. 70.

Reflections on the status of immunization and therapy. Carl R. Woodward. Nov. 1977, p. 12.

Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.

"Without batting an eye," in Washington report. James Dickinson. May 1978, p. 64.

ASSAY AND BIOASSAY METHODS

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

AUDITS

FDA's CGMP regulations and quality audits. Jonas L. Bassen. July 1977, p. 31.

Regulatory affairs: Audits. Thomas H. Riggs. Oct. 1977, p. 24.

AUTOMATION

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.

Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.

An automated dispensing and data-collection system. Thomas R. Lloyd. Dec. 1977, p. 20.

Automated HPLC systems: a total approach. John C. MacDonald. April 1978, p. 78.

Automated microscopy for contamination control. Barbara Clements and Ronald Swenson. Jan. 1978, p. 42.

Automated plate-counting assays in the Ames *Salmonella*/microsome mutagenicity test. David J. Brusick. Jan. 1978, p. 37.

Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.

The automation of cell-culture techniques. Mona D. Jensen. Feb. 1978, p. 22.

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.

Drug-safety evaluation using computerized data processing. John L. Robertson. May 1978, p. 50.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

Instrumentation in futuristic pharmaceutics. Victor F. Smolen. April 1978, p. 10.

Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.

Predicting the time course of in vivo bioavailibility from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

Production-line visual recognition systems. Harvey L. Kasdan. Aug. 1977, p. 18.

Solving the puzzle of random variables in dissolution testing. William A. Hanson. Oct. 1977, p. 30.

Tablet coating: ladles to computers. David B. Huberfield. Oct. 1977, p. 52.

The threshold of a new drug-production era. James Dickinson. Feb. 1978, p. 41.

The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

BACTERIOLOGY (see also MICROBIOLOGY)

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

BIOAVAILABILITY AND BIOEQUIVALENCE

The battle is over, but . . . William F. Haddad. May 1979, p. 10.

Bioavailability and bioequivalence regulations: an FDA perspective. Gene Knapp. July 1978, p. 22.

Bioavailability and bioequivalence regulations: how they will impact on product development? John W. Poole. July 1978, p. 28.

Bioavailability and bioequivalence regulations: an overview. James T. Doluisio. July 1978, p. 32.

"Bioavailability boondoggle," in Washington report. James Dickinson. July 1977, p. 16.

Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.

"Can you beat a MAC?" in Washington report. James Dickinson. Aug. 1979, p. 13.

"DESI's biggest compliance project," in Washington report. James Dickinson. Sept. 1979, p. 30.

A drug by any other name . . . ? C. Joseph Stetler. July 1978, p. 8.

Drug-product substitution and therapeutic equivalence. J. Richard Crout. June 1979, p. 56.
"During its struggle," in Washington report. James Dickinson. April 1978, p. 24.
"Equivalence v. interchangeability," in Washington report. James Dickinson. Feb. 1979, p. 17.
"FDA's first bioequivalence requirements," in Washington report. James Dickinson. Oct. 1977, p. 20.
"FDA's increasingly heavy emphasis," in Washington report. James Dickinson. Dec. 1977, p. 12.
Implementation of the bioavailability/bioequivalence regulations. Jerome P. Skelly. Jan. 1978, p. 28.
In vitro drug-product bioequivalency requirements: what can they become? Victor F. Smolen. Sept. 1977, p. 26.
London letter. Peter Bathe. Sept. 1979, p. 33.
"Out of its bioequivalence depth?" in Washington report. James Dickinson. Oct. 1978, p. 16.
"Pharmacokinetics," in Washington report. James Dickinson. Aug. 1977, p. 15.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
"Tablets of stone," in Washington report. James Dickinson. Jan. 1979, p. 20.
Therapeutic equivalence in a restructured drug market. James Dickinson. April 1979, p. 72.

BULKING AGENTS

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

CAPSULES

"A cavalier attitude," in Washington report. James Dickinson. March 1978, p. 20.
Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.
"Inadequate attention to cleaning," in Washington report. James Dickinson. July 1979, p. 17.
Soft elastic gelatin capsules: a unique dosage form. William R. Ebert. Oct. 1977, p. 44.
The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

CHROMATOGRAPHY

Automated HPLC systems: a total approach. John C. MacDonald. April 1978, p. 78.
The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

CLOSURES, RUBBER

Improved procedures for selection of rubber closures. George H. Hopkins. June 1978, p. 8.
Pretreatment of rubber closures for parenteral containers. John Kapoor and Ram Murty. Nov. 1977, p. 53.

COATINGS

Aqueous film coating: an overview. Stuart C. Porter. Sept. 1979, p. 54.
Cellulose acetate phthalate: a versatile enteric coating. Gerald T. Luce. June 1977, p. 27.
Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.
The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.
Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.
Tablet coatings: ladles to computers. David B. Huberfield. Oct. 1977, p. 52.

COMPUTERS (see AUTOMATION)

CONTAMINATION (see also PYROGENS; STERILIZATION)

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Automated microscopy for contamination control. Barbara Clements and Ronald Swenson. Jan. 1978, p. 42.
Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Filter sizing for economics: liquid systems. Jack C. Cole and Robert H. Shumsky. Nov. 1977, p. 38.
Further observations on a practical method for the microbiological examination of OTC products. Carl R. Woodward Jr. and Marianne Steinbach. June 1977, p. 39.
Identification of parenteral particulate contaminants. Walter C. McCrone. May 1978, p. 56.
In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
Microporous-filter sanitization of large-volume product and feed-water systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.
Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.
Particulate matter in parenteral products. May 1979, p. 30.
Pretreatment of rubber closures for parenteral containers. John Kapoor and Ram Murty. Nov. 1977, p. 53.
Quality assurance and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.
Raw material microbial-count reduction via cobalt-60 irradiation. David G. Pope, Kiyoshi Tsuji, John H. Robertson, and Melvin J. DeGeeter. Oct. 1978, p. 30.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

CONTROLLED RELEASE

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.

COSMETICS

The extension of drug industry practice to cosmetics manufacture. Theodore H. Meltzer. Dec. 1977, p. 14.
"FDA's cosmetic GMPs," in Washington report, James Dickinson. July 1977, p. 16.
"Last of the robber barons," in Washington report. James Dickinson. April 1978, p. 26.

COST CONTAINMENT

The pharmacist's role in health-care cost containment. Joseph A. Oddis. Nov. 1978, p. 8.
Self-policing and free enterprise: an interview with Representative Paul Rogers. James Dickinson. April 1978, p. 61.

DISSOLUTION AND DISINTEGRATION

Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.
Can dissolution testing be a precise method? William A. Hanson. Aug. 1979, p. 8.

Disintegration of tablets enteric coated with cellulose acetate phthalate. Gerald T. Luce. Oct. 1978, p. 51.
Dissolution standards in USP. Daniel Banes. Aug. 1978, p. 46.
"Dissolution's worst test," Washington report. James Dickinson. Jan. 1979, p. 19.
Dissolution testing: it's increasing role. Gene Knapp. Sept. 1977, p. 12.
Dissolution testing — need for standardization. Jerome P. Skelly. Oct. 1977, p. 12.
Effects of moisture on the dissolution rate of prednisone tablets. William A. Hanson and Royal A. Hanson. March 1979, p. 42.
"FDA's increasingly heavy emphasis," in Washington report. James Dickinson. Dec. 1977, p. 12.
Guidelines for dissolution testing. Don C. Cox, Carol C. Douglas, William B. Furman, Ross D. Kirchhoefer, James W. Myrick, and Clyde E. Wells. April 1978, p. 40.
In vitro drug-product bioequivalency requirements: what can they become? Victor F. Smolen. Sept. 1977, p. 26.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
Solving dissolution problems with solid dispersions. James W. McGinity. March 1978, p. 50.
Solving the puzzle of random variables in dissolution testing. William A. Hanson. Oct. 1977, p. 30.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

DRUG PRODUCT PROBLEM REPORTING SYSTEM

Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.

DRUG THERAPY

Reflections on the status of immunization and therapy. Carl R. Woodward. Nov. 1977, p. 12.

DRYING

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

EDUCATION

Financial support for graduate education. Varro E. Tyler. Feb. 1978, p. 8.

EFFICACY

"An unrealistic timetable," in Washington report. James Dickinson. May 1979, p. 14.

EMPLOYMENT

Interviews that win jobs. James A. Crumpley. Oct. 1979, p. 42.
Job hunting: a professional approach. James A. Crumpley. June 1979, p. 45.

ENGINEERING

Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.

EQUIPMENT

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

EXCIPIENTS

Excipients and dosage-form development. Jack Cooper. April 1979, p. 12.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

FILMS

The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.
Some factors that affect the properties of mixed films of acrylic. A.A. Kassem, S.A.M. Abdel-Aziz, A.E. Abou-Taleb, and S.S. Abdel-Hady. Sept. 1979, p. 70.

FILTRATION

Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.
Considerations in application of bacteria-retentive air vent-filters. Jack C. Cole. June 1977, p. 49.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
The extension of drug industry practice to cosmetics manufacture. Theodore H. Meltzer. Dec. 1977, p. 14.
Filter sizing for economics: liquid systems. Jack C. Cole and Robert H. Shumsky. Nov. 1977, p. 38.
Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.
Membrane-filter characterizations and their implications for particulate retention. Raymond C. Lukaszewicz, Gerald B. Tanny, and Theodore H. Meltzer. Nov. 1978, p. 76.
Microporous-filter sanitization of large-volume product and feedwater systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.
Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.
Recycling-tangential flow in microporous cartridge filtration. William D. Bickmore Jr., Rudolph A. Champa, and Wayne P. Olson. Nov. 1977, p. 55.
Removal of pyrogens from parenteral solutions by ultrafiltration. Lita L. Nelsen. May 1978, p. 46.
Ultrafiltration in plasma fractionation. Lita L. Nelsen and Adrian R. Reti. May 1979, p. 50.
Validation of bacterial-retention capabilities of membrane filters. Timothy J. Leahy and Mary J. Sullivan. Nov. 1978, p. 64.
Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

FLUORESCENCE

The use of x-ray fluorescence in control of pharmaceutical products. David Stewart. April 1978, p. 54.

FOOD AND DRUG ADMINISTRATION

Bioavailability and bioequivalence regulations: an FDA perspective. Gene Knapp. July 1978, p. 22.
Bioavailability and bioequivalence regulations: how will they impact on product development? John W. Poole. July 1978, p. 28.
Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.
FDA's CGMP regulations and quality audits. Jonas L. Bassen. July 1977, p. 31.
FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
FDA's Kennedy has a prescription for drug science: upgrade toxicology. James Dickinson. June 1978, p. 60.
FDA yields to industry positions on Good Manufacturing Practices. James Dickinson. Dec. 1978, p. 25.
A government success story. Joseph P. Hile. June 1977, p. 45.
Human injectable drugs: an FDA perspective. Bernard T. Loftus. Nov. 1977, p. 44.

The imperatives of drug-law revision. Donald Kennedy. Jan. 1978, p. 10.
Industry-agency relations: an interview with J. Richard Crout. James Dickinson. March 1978, p. 39.
Innovation and the drug reform act of 1978. Gerald C. Laubach. Aug. 1978, p. 14.
Prescription for an FDA commissioner. Louis Lasagna. Oct. 1979, p. 14.
Public monographs: The centerpiece of the new drug bill. James Dickinson. May 1978, p. 37.
Self-policing and free enterprise: an interview with Representative Paul Rogers. James Dickinson. April 1978, p. 61.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Washington report. James Dickinson. Monthly column. June 1977–Dec. 1979.

FOOD, DRUG, AND COSMETIC ACT

Devices decrease drug domination. Thomas H. Riggs. June 1977, p. 31.
A government success story. Joseph P. Hile. June 1977, p. 45.
"Out with the FD&C Act," in Washington report. James Dickinson. Feb. 1978, p. 15.
"Safety — absolute versus relative. Thomas H. Riggs. Aug. 1977, p. 37.

FREE ENTERPRISE

The drug reform act: a reprieve. Ted Rowell Jr. March 1979, p. 8.
Economic incentive: the key to cost-effective medicine. C. Joseph Stetler. July 1979, p. 20.
Self-policing and free enterprise: an interview with Representative Paul Rogers. James Dickinson. April 1978, p. 61.

FREEZE DRYING

How to select a pharmaceutical freeze-drying system. Stanley L. Morgan and Marlin R. Spotts. Nov. 1979, p. 94.
Special design considerations for large-production freeze dryers. Edward A. Stanford and Thomas J. Wardle. Nov. 1977, p. 59.

FRUCTOSE

Tableting characteristics of pure crystalline fructose. Thomas F. Osberger. June 1979, p. 80.

GENERIC DRUGS

"Are generics 'interchangeable'?" in Washington report. James Dickinson. Aug. 1978, p. 17.
The battle is over, but. . . . William F. Haddad. May 1979, p. 10.
"Dragged kicking and screaming," in Washington report. James Dickinson. April 1978, p. 20.
Economic incentive: the key to cost-effective medicine. C. Joseph Stetler. July 1979, p. 20.
"False disparagement," in Washington report. James Dickinson. Oct. 1979, p. 26.
"FDA's generic-drug role threatened," in Washington report. James Dickinson. Dec. 1978, p. 55.
"PMA as Public Enemy No. 1," in Washington report. James Dickinson. Sept. 1978, p. 17.
"Son of bioequivalence," in Washington report. James Dickinson. Feb. 1979, p. 17.

GOOD LABORATORY PRACTICES

The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
"FDA's upcoming GLP regulations," in Washington report. James Dickinson. Nov. 1977, p. 74.
"Goaded by abuse disclosures," in Washington report. James Dickinson. March 1979, p. 17.
The impact of GLP regulations on an industrial toxicology laboratory. Hans P. Drobeck. Aug. 1979, p. 34.
"A naked power grab," in Washington report. James Dickinson. Sept. 1977, p. 16.
Quality assurances and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.
"Quality Assurance Units," in Washington report. James Dickinson. Sept. 1977, p. 17.

GOOD MANUFACTURING PRACTICES

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
Devices decrease drug domination. Thomas H. Riggs. June 1977, p. 31.
The extension of drug industry practice to cosmetics manufacture. Theodore H. Meltzer. Dec. 1977, p. 14.
FDA's CGMP regulations and quality audits. Jonas L. Bassen. July 1977, p. 31.
"FDA's cosmetic GMPs," in Washington report. James Dickinson. July 1977, p. 16.
"FDA's new GMP regulations," in Washington report. James Dickinson. May 1978, p. 62.
FDA yields to industry positions on Good Manufacturing Practices. James Dickinson. Dec. 1978, p. 25.
"The flexibility of the new CGMPs," in Washington report. James Dickinson. June 1979, p. 12.
"Goaded by abuse disclosures," in Washington report. James Dickinson. March 1979, p. 17.
A government success story. Joseph P. Hile. June 1977, p. 45.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979. p. 52.
"Inadequate attention to cleaning," in Washington report. James Dickinson. July 1979, p. 17.
In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
No new nonofficial drugs. Thomas H. Riggs. June 1977, p. 18.
The point of the Pinto. Thomas H. Riggs. May 1978, p. 14.
Quality assurance and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.
The real GMPs. Frank D. Eaton. Nov. 1978, p. 58.
"So what about GMPs?" in Washington report. James Dickinson. Feb. 1978, p. 16.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Understanding and utilizing F_0 values. Michael J. Akers, Ismail A. Attia, and Kenneth E. Avis. May 1978, p. 30.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

GRANULATION

Advantages of continuous tablet granulation. Sept. 1979, p. 49.
Theory of the granulating-liquid requirement in the conventional granulation process. Hans Leuenberger, Hans-Peter Bier, and Heinz B. Sucker. June 1979, p. 60.

HAZARDOUS MATERIALS

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.

HISTORY OF PHARMACY

The development of the modern pharmaceutical industry. John Parascandola. Oct. 1979, p. 46.

IMMUNIZATION

Reflections on the status of immunization and therapy. Carl R. Woodward. Nov. 1977, p. 12.

IMPACTORS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

INK

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

INSTRUMENTATION

Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.

Applications of the osmometer in the manufacture of certain parenteral preparations. Ram Murty and John Kapoor. July 1977, p. 37.

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

Solving the puzzle of random variables in dissolution testing. William A. Hanson. Oct. 1977, p. 30.

The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

INSULIN

Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

INVESTIGATIONAL NEW DRUG APPLICATIONS (INDs)

"In vitro/in vivo," in Washington report. James Dickinson. Oct. 1977, p. 20.

"It looked like a witch-hunt," in Washington report. James Dickinson. May 1978, p. 19.

"Published studies are not reliable," in Washington report. James Dickinson. Dec. 1979, p. 62.

" 'Substantive changes' in IND regulations," in Washington report. James Dickinson. Oct. 1977, p. 73.

IRON DEFICIENCY

Iron deficiency: a challenge to the pharmaceutical industry. Leif Hallberg, Selwyn J. Baker, C.O. Chichester, James D. Cook, E.M. DeMaeyer, Harold Newmark, H. Louis Shapiro, and Lester J. Teply. Oct. 1979, p. 34.

LABELING

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

Industry-agency relations: an interview with J. Richard Crout. James Dickinson. March 1978, p. 39.

In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.

"The next industry/FDA battleground," in Washington report. James Dickinson. Dec. 1978, p. 11.

Pressure-sensitive labels: standards in quality control. Christopher Bell. June 1978, p. 56.

Public monographs: the centerpiece of the new drug bill. James Dickinson. May 1978, p. 37.

Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.

LAL (see *LIMULUS* AMOEBOCYTE LYSATE)

LAMINAR FLOW

Short-term hot-air sterilization by the laminar-flow process. Wilfried G. Willing. May 1979, p. 68.

***LIMULUS* AMOEBOCYTE LYSATE**

An inquiry into the LAL and rabbit pyrogen tests. Daniel Banes. July 1979, p. 28.

LUBRICANTS

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

LYOPHILIZATION (see FREEZE DRYING)

MAXIMUM ALLOWABLE COST (MAC)

"Can you beat a MAC?" in Washington report. James Dickinson. Aug. 1979, p. 13.

"Drugs in national health insurance," in Washington report. James Dickinson. Dec. 1978, p. 15.

"The MAC program is back," in Washington report. James Dickinson. Nov. 1978, p. 118.

"MAC seems unstoppable," in Washington report. James Dickinson. Aug. 1978, p. 20.

"Tablets of stone," in Washington report. James Dickinson. Jan. 1979, p. 20.

MEDICAL DEVICES

Devices decrease drug domination. Thomas H. Riggs. June 1977, p. 31.

METERS

A natural gas metering system. Rick Challman. Dec. 1978, p. 36.

MICROBIOLOGY (see also ANAEROBES; BACTERIOLOGY)

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.

Automated plate-counting assays in the Ames *Salmonella*/microsome mutagenicity test. David J. Brusick. Jan. 1978, p. 37. Jan. 1978, p. 37.

The automation of cell-culture techniques. Mona D. Jensen. Feb. 1978, p. 22.

Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.

Considerations in application of bacteria-retentive air-vent filters. Jack C. Cole. June 1977, p. 49.

Further observations on a practical method for the microbiological examination of OTC products. Carl R. Woodward Jr. and Marianne Steinbach. June 1977, p. 39.

Identification of clinically significant anaerobic bacteria. Allen Borowsky. Jan. 1979, p. 32.

Quality assurance and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.

Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.

MICROCAPSULES

Methods of preparing microcapsules: coacervation, or phase separation. Parshotam L. Madan. Feb. 1978, p. 30.

Methods of preparing microcapsules: interfacial polymerization. Parshotam L. Madan. Sept. 1978, p. 68.

Methods of preparing microcapsules: mechanical methods. Parshotam L. Madan. Aug. 1978, p. 24.

Microencapsulation: an overview. Parshotam L. Madan. Dec. 1977, p. 28.

MICROSCOPY

Automated microscopy for contamination control. Barbara Clements and Ronald Swenson. Jan. 1978, p. 42.

Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.

Tablets under the microscope. Hans Hess. Sept. 1978, p. 36.

MIXERS

The Day-Nauta mixer-processor. Edward J. Shevlin. March 1978, p. 56.

MODELS

A Weibull shelf-life model for pharmaceuticals. John E. Ogden. Oct. 1978, p. 44.

MOISTURE

How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

MULTIVARIATE STATISTICAL ANALYSIS (see STATISTICS)

MUTAGENS

Automated plate-counting assays in the Ames *Salmonella*/microsome mutagenicity test. David J. Brusick. Jan. 1978, p. 37.

NEW DRUG APPLICATIONS (NDAs) (see also INVESTIGATIONAL NEW DRUG APPLICATIONS)

"Bioregulations are invalid," in Washington report. James Dickinson. Nov. 1978, p. 114.

"FDA promises faster NDA's," in Washington report. James Dickinson. Feb. 1979, p. 22.

"FDA's policy regarding 'paper' NDAs," in Washington report. James Dickinson. Dec. 1979, p. 14.

"FDA will withdraw Geigy NDAs," in Washington report. James Dickinson. Oct. 1977, p. 73.

"Milton Bass talks," in Washington report. James Dickinson. July 1979, p. 16.

"A naked power grab," in Washington report. James Dickinson. Sept. 1977, p. 16.

" 'Paper' NDAs," in Washington report. James Dickinson. Sept. 1979, p. 26.

"Pharmadyne as phoenix?" in Washington report. James Dickinson. July 1979, p. 17.

Public image, patent status, and "paper" NDAs: an FDA roundtable. Diana Rico. July 1979, p. 32.

"Speeding up the NDA process," in Washington report. James Dickinson. Oct. 1977, p. 19.

"Tougher ANDA rules," in Washington report. James Dickinson. Nov. 1978, p. 117.

NONOFFICIAL DRUGS

No new nonofficial drugs. Thomas H. Riggs. June 1977, p. 18.

OFFICE OF FEDERAL PROCUREMENT POLICY

A government-wide approach to quality assurance. Hugh E. Witt. June 1977, p. 44.

OXYTOCIN

The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.

PACKAGING

Improved procedures for selection of rubber closures. George H. Hopkins. June 1978, p. 8.

Lot-size determination for multipackage products. William R. Barr and Harry H. Cotterill. March 1978, p. 46.

Pressure-sensitive labels: standards in quality control. Christopher Bell. June 1978, p. 56.

"Unit-of-use packaging," in Washington report. James Dickinson. Nov. 1979, p. 34.

"Unit-of-use packaging is on the way," in Washington report. James Dickinson. May 1979, p. 20.

Use of regression analysis in packaging inspection. Marvin Sirota, Michael Kamowski, and Mark Wozniak. June 1978, p. 40.

PARENTERALS

Applications of the osmometer in the manufacture of certain parenteral preparations. Ram Murty and John Kapoor. July 1977, p. 37.

Biocontainment process station for parenteral manufacturing. Joachim E. Manning. Nov. 1979, p. 78.

Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.

Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.

"A far cry from the GLPs," in Washington report. James Dickinson. March 1979, p. 25.

Filter sizing for economics: liquid systems. Jack C. Cole and Robert H. Shumsky. Nov. 1977, p. 38.

Human injectable drugs: an FDA perspective. Bernard T. Loftus. Nov. 1977, p. 44.

Identification of parenteral particulate contaminants. Walter C. McCrone. May 1978, p. 56.

Improved procedures for selection of rubber closures. George H. Hopkins. June 1978, p. 8.

In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.

Parenteral drugs: a lawyer's viewpoint. George M. Burditt. May 1978, p. 12.

Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.

Particulate matter in parenteral products. May 1979, p. 30.

Pretreatment of rubber closures for parenteral containers. John Kapoor and Ram Murty. Nov. 1977, p. 53.

Recycling-tangential flow in microporous cartridge filtration. William D. Bickmore Jr., Rudolph A. Champa, and Wayne P. Olson. Nov. 1977, p. 55.

Reflections on the status of immunization and therapy. Carl R. Woodward Jr. Nov. 1977, p. 12.

Removal of pyrogens from parenteral solutions by ultrafiltration. Lita L. Nelsen. May 1978, p. 46.

Understanding and utilizing F_0 values. Michael J. Akers, Ismail A. Attia, and Kenneth E. Avis. May 1978, p. 30.

Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

PARTICULATES

Automated microscopy for contamination control. Barbara Clements and Ronald Swenson. Jan. 1978, p. 42.

The extension of drug industry practice to cosmetics manufacture. Theodore H. Meltzer. Dec. 1977, p. 14.

Filter sizing for economics: liquid systems. Jack C. Cole and Robert H. Shumsky. Nov. 1977, p. 38.

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.

Identification of parenteral particulate contaminants. Walter C. McCrone. May 1978, p. 56.

In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.

Membrane-filter characterizations and their implications for particulate retention. Raymond C. Lukaszewicz, Gerald B. Tanny, and Theodore H. Meltzer. Nov. 1978, p. 76.

Microporous-filter sanitization of large-volume product and feedwater systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.

Particulate-matter detection in LVPs and IV sets: automated microscopic and Coulter-counter methods. James W. Warren Jr., Thomas E. Needham Jr., and Joseph D. Benmaman. Dec. 1978, p. 30.

Particulate matter in parenteral products. May 1979, p. 30.

Pretreatment of rubber closures for parenteral containers. John Kapoor and Ram Murty. Nov. 1977, p. 53.

Recycling-tangential flow in microporous cartridge filtration. William D. Bickmore Jr., Rudolph A. Champa, and Wayne P. Olson. Nov. 1977, p. 55.

Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

PATIENT PACKAGE INSERTS

"Concern over the U.S. 'drug lag,' " in Washington report. James Dickinson. Nov. 1977, p. 18.
" 'Generic' patient package inserts," in Washington report. James Dickinson. March 1979, p. 20.
"On patient package inserts," in Washington report. James Dickinson. Nov. 1977, p. 20.
Patient package inserts. C. Joseph Stetler. Aug. 1977, p. 10.
A year for drug-law reform. Donald Kennedy. Jan. 1979, p. 16.

PERSONNEL

Training personnel to work in sterile environments. Franco A. De Vecchi. Aug. 1978, p. 40.

PHARMACEUTICAL TECHNOLOGY

An automated dispensing and data-collection system. Thomas R. Lloyd. Dec. 1977, p. 20.
First International Conference on Pharmaceutical Technology. Patrick P. DeLuca. Aug. 1977, p. 34.

PHARMACY

Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.

PIGMENTS (see also INKS)

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.
The effect of a coloring agent on properties of mixed films of acrylic. S.A.M. Abdel-Aziz, A.A. Kassem, A.E. Abou-Taleb, and S.S. Abdel-Hady. Dec. 1979, p. 38.

PLASMA

Ultrafiltration in plasma fractionation. Lita L. Nelsen and Adrian R. Reti. May 1979, p. 50.

POWDERS

Quality assurance and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.

PRECIPITATORS

Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.

PREDNISONE

"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
Effects of moisture on the dissolution rate of prednisone tablets. William A. Hanson and Royal A. Hanson. March 1979, p. 42.
" 'Generic' patient package inserts," in Washington report. James Dickinson. March 1979, p. 20.

PROCESSING

In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.

PROCUREMENT, FEDERAL

A government success story. Joseph P. Hile. June 1977, p. 45.
A government-wide approach to quality assurance. Hugh E. Witt. June 1977, p. 44.

PRODUCTIVITY

Drug-firm productivity, R&D, and public policy. Douglas L. Cocks. Sept. 1977, p. 20.

PROPOXYPHENE

"Ah, sweet elixir of propoxyphene!" in Washington report. James Dickinson. April 1979, p. 16.
"Whatever FDA does is wrong," in Washington report. James Dickinson. Nov. 1979, p. 32.

PYROGENS (see also CONTAMINATION; STERILIZATION)

Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.
An inquiry into the LAL and rabbit pyrogen tests. Daniel Banes. July 1979, p. 28.
Removal of pyrogens from parenteral solutions by ultrafiltration. Lita L. Nelsen. May 1978, p. 46.

QUALITY ASSURANCE AND CONTROL

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.
Aseptic control: where to start. Joachim E. Manning and Jim Moore. June 1977, p. 54.
An automated dispensing and data-collection system. Thomas R. Lloyd. Dec. 1977, p. 20.
Automated HPLC systems: a total approach. John C. McDonald. April 1978, p. 78.
Automated microscopy for contamination control. Barbara Clements and Ronald Swenson. Jan. 1978, p. 42.
Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.
Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.
Drug-quality regulation and the pursuit of excellence. James Dickinson. Aug. 1978, p. 21.
Drug quality: who has the answer? Robert J. Creevy. Feb. 1979, p. 10.
Drug-safety evaluation using computerized data processing. John L. Robertson. May 1978, p. 50.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.
FDA's CGMP regulations and quality audits. Jonas L. Bassen. July 1977, p. 31.
A government success story. Joseph P. Hile. June 1977, p. 45.
A government-wide approach to quality assurance. Hugh E. Witt. June 1977, p. 44.
How to select a pharmaceutical freeze-drying system. Stanley L. Morgan and Marlin R. Spotts. Nov. 1979, p. 94.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
Pressure-sensitive labels: standards in quality control. Christopher Bell. June 1978, p. 56.
Production-line visual recognition systems. Harvey L. Kasdan. Aug. 1977, p. 18.
Quality assurance and quality control of commercially prepared microbiological powder media. John R. Dixon. Aug. 1977, p. 27.
"Quality Assurance Units," in Washington report. James Dickinson. Sept. 1977, p. 17.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.
The use of HPLC in the quality control of oxytocin. Kurt Krummen, Friedrich Maxl, and Friedrich Nachtmann. Sept. 1979, p. 76.
The use of x-ray fluorescence in control of pharmaceutical products. David Stewart. April 1978, p. 54.

UV/Vis spectrophotometers: quality control and troubleshooting. Leo E. Clougherty. April 1978, p. 68.
Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.
Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

RADIATION

Radiosterilization in industry today. Michael G. Fogarty. June 1978, p. 34.
Raw material microbial-count reduction via cobalt-60 irradiation. David G. Pope, Kiyoshi Tsuji, John H. Robertson, and Melvin J. DeGeeter. Oct. 1978, p. 30.

RADIOPHARMACEUTICALS

A fortress for radiopharmaceuticals. Aug. 1979, p. 32.

REGULATIONS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
As I see it. Edward S. Brady. Feb. 1979, p. 41.
Bioavailability and bioequivalence regulations: an FDA perspective. Gene Knapp. July 1978, p. 22.
Bioavailability and bioequivalence regulations: how will they impact on product development? John W. Poole. July 1978, p. 28.
Bioavailability and bioequivalence regulations: an overview. James T. Doluisio. July 1978, p. 32.
The challenge of self-regulation. C. Joseph Stetler. June 1979, p. 8.
"A change in antibiotic regulations," in Washington report. James Dickinson. Oct. 1977, p. 73.
Communication of attitude as a regulatory factor. Thomas H. Riggs. Oct. 1978, p. 27.
"Concern over the U.S. 'drug lag,' " in Washington report. James Dickinson. Nov. 1977, p. 18.
"Consensus leaves the drug bill," in Washington report. James Dickinson. July 1978, p. 16.
"DEA decontrols 141 drugs," in Washington report. James Dickinson. Jan. 1978, p. 61.
Devices decrease drug domination. Thomas H. Riggs. June 1977, p. 31.
"The drug bill's demise," in Washington report. James Dickinson. Oct. 1978, p. 14.
Drug-quality surveillance of Rx and OTC drug products. Arvin P. Shroff. Dec. 1979, p. 28.
The drug reform act: a reprieve. Ted Rowell Jr. March 1979, p. 8.
Drug regulation in the public interest. Preston S. Parish. Sept. 1978, p. 8.
"The Drug Regulation Reform Act," in Washington report. James Dickinson. Aug. 1978, p. 68.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
FDA's CGMP regulations and quality audits. Jonas L. Bassen. July 1977, p. 31.
FDA's Good Laboratory Practice regulations. Paul D. Lepore. June 1979, p. 70.
FDA's Kennedy has a prescription for drug science: upgrade toxicology. James Dickinson. June 1978, p. 60.
FDA yields to industry positions on Good Manufacturing Practices. James Dickinson. Dec. 1978, p. 25.
"Good-bye Rogers, good-bye drug bill?" in Washington report. James Dickinson. Dec. 1978, p. 12.
A government success story. Joseph P. Hile. June 1977, p. 45.
A government-wide approach to quality assurance. Hugh E. Witt. June 1977, p. 44.
The impact of GLP regulations on an industrial toxicology laboratory. Hans P. Drobeck. Aug. 1979, p. 34.
The imperatives of drug-law revision. Donald Kennedy. Jan. 1978, p. 10.
Implementation of the bioavailability/bioequivalence regulations. Jerome P. Skelly. Jan. 1978, p. 28.
Industry-agency relations: an interview with J. Richard Crout. James Dickinson. March 1978, p. 39.
"Industry won't feel the teeth," in Washington report. James Dickinson. June 1978, p. 15.
Innovation and the drug reform act of 1978. Gerald D. Laubach. Aug. 1978, p. 14.
In vitro drug-product bioequivalency requirements: what can they become? Victor F. Smolen. Sept. 1977, p. 26.
IRLG. Thomas H. Riggs. Aug. 1978, p. 52.
"Last chance for drug-law reform?" in Washington report. James Dickinson. May 1979, p. 18.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
London Letter. Peter Bathe. Oct. 1979, p. 29.
"Look-alike drug products," in Washington report. James Dickinson. Oct. 1979, p. 24.
"Man-in-the-plant," in Washington report. James Dickinson. Nov. 1978, p. 14.
"Milton Bass talks," in Washington report. James Dickinson. July 1979, p. 16.
"On patient package inserts," in Washington report. James Dickinson. Nov. 1977, p. 20.
"Out with the FD&C Act," in Washington report. James Dickinson. Feb. 1978, p. 15.
Parenteral drugs: a lawyer's viewpoint. George M. Burditt. May 1978, p. 12.
The pharmaceutical industry today. George H. Hopkins. June 1977, p. 16.
The point of the Pinto. Thomas H. Riggs. May 1978, p. 14.
Public monographs: The centerpiece of the new drug bill. James Dickinson. May 1978, p. 37.
The real GMPs. Frank D. Eaton. Nov. 1978, p. 58.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
Self-policing and free enterprise: an interview with Representative Paul Rogers. James Dickinson. April 1978, p. 61.
"Senator Kennedy holds the key," in Washington report. James Dickinson. Nov. 1979, p. 40.
"Senator Kennedy is closer," in Washington report. James Dickinson. Nov. 1977, p. 18.
Stability. Thomas H. Riggs. Jan. 1978, p. 21.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
$10,000 per day? Thomas H. Riggs. Feb. 1978, p. 66.
Therapeutic equivalence in a restructured drug market. James Dickinson. April 1979, p. 72.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.
A year for drug-law reform. Donald Kennedy. Jan. 1979, p. 16.

RESEARCH AND DEVELOPMENT

A commitment to excellence and awareness. Patrick P. DeLuca. July 1979, p. 10.
Drug-firm productivity, R&D, and public policy. Douglas L. Cocks. Sept. 1977, p. 20.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
Prospects for the 1980s. John J. Horan. Sept. 1979, p. 24.
"Upjohn has the best erythromycin," in Washington report. James Dickinson. June 1979, p. 18.

RESINS

Coating small particles with acrylic resins. Klaus Lehmann and Dieter Dreher. March 1979, p. 52.
Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

SAFETY

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.

Safety — absolute versus relative. Thomas H. Riggs. Aug. 1977, p. 37.

SAMPLING

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.
Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
Free air monitoring of nonviable aerosol particles: part I. Alvin Lieberman. Feb. 1979, p. 70.
Free air monitoring of nonviable aerosol particles: part II. Alvin Lieberman. March 1979, p. 60.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
"A tough new campaign," in Washington report. James Dickinson. Dec. 1977, p. 12.

SOLVENTS

Edible printing inks. Donald N. Lykens. Feb. 1979, p. 56.

SORBENTS

Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.

SPECTROPHOTOMETRY (see also SPECTROSCOPY)

Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.
UV/Vis spectrophotometers: quality control and troubleshooting. Leo C. Clougherty. April 1978, p. 68.

SPECTROSCOPY

Computerized infrared techniques for pharmaceutical-formulation quality control. Robert J. Obremski and J. William Mohar. April 1979, p. 58.
The use of Fourier-transform infrared spectroscopy in quality assurance. Warren A. McAllister, Frederick D. Sancilio, and G. William Martin. April 1979, p. 50.

STABILITY

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
Stability. Thomas H. Riggs. Jan. 1978, p. 21.
A Weibull shelf-life model for pharmaceuticals. John E. Ogden. Oct. 1978, p. 44.

STANDARDS

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
Dissolution standards in USP. Daniel Banes. Aug. 1978, p. 46.
"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
The effects of the new GLP regulations on nonclinical biomedical research. Walter C. Gakenheimer. Dec. 1979, p. 34.
Pressure-sensitive labels: standards in quality control. Christopher Bell. June 1978, p. 56.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.

STATISTICS

Acceptance sampling for small fraction defectives. Carlos W. Moreno and Allan T. Reeves. July 1979, p. 40.
Multivariate statistical analysis in pharmaceutical research. Allan R. Sampson. Jan. 1979, p. 36.
Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.

STERILIZATION (see also CONTAMINATION; PYROGENS)

Aseptic control: where to start. Joachim E. Manning and Jim Moore. June 1977, p. 54.
Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Filter sizing for economics: liquid systems. Jack C. Cole and Robert H. Shumsky. Nov. 1977, p. 38.
How to specify equipment for dry-heat sterilization and drying of pharmaceuticals. Bud Hauser. Oct. 1979, p. 52.
In-process controls during the manufacture of injectables. Ram Murty, John Kapoor, and Gary Franklin. Nov. 1977, p. 52.
Legal implications of the absolute sterility concept. Rodney R. Munsey. Nov. 1979, p. 56.
Pretreatment of rubber closures for parenteral containers. John Kapoor and Ram Murty. Nov. 1977, p. 53.
Radiosterilization in industry today. Michael G. Fogarty. June 1978, p. 34.
Short-term hot-air sterilization by the laminar-flow process. Wilfried G. Willing. May 1979, p. 68.
Steam-sterilization validation studies for manufacturing equipment. Michael Enzinger, Arnold D. DeVisser, and Michael W. Townsend. Aug. 1977, p. 31.
Sterilizer validation. Paul L. Simmons. April 1979, p. 68.
Thermal solution sterilization. Frank E. Halleck. June 1978, p. 48.
Training personnel to work in sterile environments. Franco A. De Vecchi. Aug. 1978, p. 40.
Understanding and utilizing F_0 values. Michael J. Akers, Ismail A. Attia, and Kenneth E. Avis. May 1978, p. 30.
Validation of bacterial-retention capabilities of membrane filters. Timothy J. Leahy and Mary J. Sullivan. Nov. 1978, p. 64.
Verifying the efficiency of air-cleanliness control systems. Alvin Lieberman. Sept. 1977, p. 32.

TABLETS AND TABLETING

Advantages of continuous tablet granulation. Sept. 1979, p. 49.
Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.
Aqueous film coating: an overview. Stuart C. Porter. Sept. 1979, p. 54.
Disintegration of tablets enteric coated with cellulose acetate phthalate. Gerald T. Luce. Oct. 1978, p. 51.
Tablet coating: ladles to computers. David B. Huberfield. Oct. 1977, p. 52.
Tableting characteristics of pure crystalline fructose. Thomas F. Osberger. June 1979, p. 80.
Tableting excipients: part I. Robert W. Mendes and Suva B. Roy. March 1978, p. 32.
Tableting excipients: part II. Robert W. Mendes and Suva B. Roy. Sept. 1978, p. 60.
Tableting excipients: part III. Robert W. Mendes and Suva B. Roy. March 1979, p. 68.
Tablets under the microscope. Hans Hess. Sept. 1978, p. 36.
The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

TEMPERATURE

Considerations in the design of hot circulating water-for-injection systems. Robert J. Giorgio. Dec. 1978, p. 18.
Probe-induced errors in temperature measurement. Clarence A. Kemper and George F. Harper. Nov. 1978, p. 48.
Thermal solution sterilization. Frank E. Halleck. June 1978, p. 48.

TESTING

Antibiotic batch certification: a regulatory device that has outlived its usefulness. George H. Schneller. Nov. 1979, p. 47.
Apparatus and instrumentation for tablet dissolution testing. James A. Miller. July 1977, p. 18.

Aspects of microbiological monitoring for nonsterile and sterile manufacturing environments. Leonard A. Dell. Aug. 1979, p. 46.
Automated plate-counting assays in the Ames *Salmonella*/microsome mutagenicity test. David J. Brusick. Jan. 1978, p. 37.
Automated pyrogen-testing system. Paul E. Mazur and Martin D. McKendrick. May 1979, p. 42.
Can dissolution testing be a precise method? William A. Hanson. Aug. 1979, p. 8.
Comments on organism-challenge levels in sterilizing-filter efficiency testing. Peter R. Johnston and Theodore H. Meltzer. Nov. 1979, p. 66.
"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
Dissolution testing: its increasing role. Gene Knapp. Sept. 1977, p. 12.
Dissolution testing — need for standardization. Jerome P. Skelly. Oct. 1977, p. 12.
"Drug carcinogenicity," in Washington report. James Dickinson. Aug. 1979, p. 16.
Evaluation of a closed system for sterility testing of parenterals. Barbara L. Green and Warren Litsky. Nov. 1979, p. 72.
Guidelines for dissolution testing. Don C. Cox, Carol C. Douglas, William B. Furman, Ross D. Kirchhoefer, James W. Myrick, and Clyde E. Wells. April 1978, p. 40.
In vitro drug-product bioequivalency requirements: what can they become? Victor F. Smolen. Sept. 1977, p. 26.
Predicting the time course of in vivo bioavailability from in vitro dissolution tests: control systems engineering approaches. Victor F. Smolen, LuAnn Ball, and Michael Scheffler. June 1979, p. 88.
"Rat tests as cancer barometers," in Washington report. James Dickinson. July 1979, p. 18.
Requirements for expiration dating and stability testing in the United States. Joel S. Davis. Oct. 1979, p. 64.
Solving the puzzle of random variables in dissolution testing. William A. Hanson. Oct. 1977, p. 30.
Some observations concerning drug testing. Edward M. Kennedy. March 1978, p. 10.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.

THEOPHYLLINE

Bioavailability of theophylline in soft-gelatin capsules. William R. Ebert. Oct. 1979, p. 60.

TOXICOLOGY

FDA's Kennedy has a prescription for drug science: upgrade toxicology. James Dickinson. June 1978, p. 60.

TRADE SECRETS

"Man-in-the-plant," in Washington report. James Dickinson. Nov. 1978, p. 14.
"Protection of trade secrets," in Washington report. James Dickinson. Oct. 1977, p. 20.
"Trade secrets," in Washington report. James Dickinson. Oct. 1977, p. 20.
"Trouble in dealing with government?" in Washington report. James Dickinson. Jan. 1978, p. 60.

TRAINING

Hazardous-chemical safety training. Nancy Kippenhan. Feb. 1979, p. 64.

ULCERS

The ulcerogenic potential of orally administered dexamethasone in the rat: a comparison of a tablet formulation to soft-gelatin-capsule formulations. Larry Caldwell, Robyn Cargill, William R. Ebert, and John J. Windheuser. July 1979, p. 52.

UNITED STATES PHARMACOPEIA

"Dissolution's worst test," in Washington report. James Dickinson. Jan. 1979, p. 19.
"FDA–USP relations — a clarification," in Washington report. James Dickinson. April 1978, p. 125.
"The future of the USP," in Washington report. James Dickinson. May 1978, p. 64.
In vitro drug product bioequivalency requirements: what can they become? Victor F. Smolen. Sept. 1977, p. 26.
No new nonofficial drugs. Thomas H. Riggs. June 1977, p. 18.
On creating a compendial organization. William M. Heller. Nov. 1979, p. 12.
"A single drug-name system," in Washington report. James Dickinson. March 1979, p. 87.
"A tough new campaign," in Washington report. James Dickinson. Dec. 1977, p. 12.
USP and antibiotic standardization. Joseph G. Valentino. Sept. 1979, p. 60.
"USP just won't be the same," in Washington report. James Dickinson. Jan. 1978, p. 16.
"USP's future," in Washington report. James Dickinson. Jan 1979, p. 19.

UNIVARIATE STATISTICAL ANALYSIS (see STATISTICS)

VALIDATION

Bulk pharmaceutical chemicals: good manufacturing practice. Samuel M. Tuthill. Feb. 1979, p. 48.
Process validation for solid dosage forms. Robert A. Nash. June 1979, p. 104.
Sterilizer validation. Paul L. Simmons. April 1979, p. 68.
Strategies for surveillance of drug quality by FDA. Richard A. Terselic and Charles F. Pyatt. Jan. 1979, p. 26.
Validating alternate laboratory assay methods. James E. Duarte and Deborah K. Vest. May 1979, p. 60.
Validation and qualification of filtration systems for bacterial removal. W.P. Olson. Nov. 1979, p. 84.

WATER FOR INJECTION

Considerations in the design of hot circulating water-for-injection systems. Robert J. Giorgio. Dec. 1978, p. 18.
Extra quality: is it a waste? Martin Kladko. May 1979, p. 22.
Microporous-filter sanitization of large-volume product and feedwater systems. Raymond C. Lukaszewicz. Aug. 1979, p. 40.